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Summary Cisplatin resistant mouse fibrosarcoma cells were isolated after fractionated irradiation in the
absence of any drug treatment. Several sublines have been established; clone SSK-rad, was used for further
studies. These cells exhibit unchanged radiosensitivity and are compared to cisplatin resistant sublines,
SSK-cis2, previously induced by low dose cisplatin exposure. Both resistant sublines are characterised by
reduced CdCI2 sensitivity, indicating enhanced metallothionein content; loss ofcisplatin resistance occurs after
10 to 25 generations and correlates with rising CdCI2 toxicity. Increase of MT is demonstrated directly by
"09Cd binding to the MT containing region after FPLC. Both sublines differ in GSH level, which is increased
only in SSK-rad, cells, and in cellular platinum content, which is reduced in SSK-cis2 cells compared to the
parental SSK cell line. These factors may contribute to cisplatin resistance but are not the main cause
responsible for the transient nature of the drug resistance observed.
Our results indicate that transient cisplatin resistance in SSK cells can be induced not only by the drug itself
but also by v-irradiation and is based on the same mechanism of increased cellular MT content.
Resistance in cancer therapy usually means chemoresistance
following drug treatment. However, resistance can also be
induced by irradiation (Hill et al., 1988; 1990b; Osmak &
Perovic, 1989). Since tumour therapy often includes both
sequential or concomitant radio-chemotherapy, it is impor-
tant to study the mechanisms leading to radiation-induced
resistance or cross-resistance.
Most of the in vitro studies on drug and radiation interac-
tion have looked into cross-resistance after drug induction
and the results are rather controversial. Findings range from
no effect (Wallner & Li, 1987; Eichholtz-Wirth et al., 1993;
Mitchell et al., 1988) to cross-resistance (Schwartz et al.,
1988; Louie et al., 1985) and even to collateral sensitivity
(Hill et al., 1988). Lehnert et al. (1989 and 1990) discuss the
contribution of GSH and its related enzymes to the radiation
response in drug resistant human tumour cells. They show
that two drug resistant sublines with different underlying
mechanisms are both radioresistant and only these sublines
are radiosensitised by GSH depletion.
There are only few publications concerned with radiation
induced drug resistance. They demonstrate altered respon-
siveness to different classes of antineoplastic agents, such as
the topoisomerase II inhibitor VP-16 (Lock & Hill, 1988),
cisplatin (Dempke et al., 1992; Hill et al., 1990c; Osmak &
Petrovic, 1989), the antimetabolic drug methotrexate (Sharma
& Schimke, 1989) as well as the development of multi-drug-
resistance (Mattern et al., 1991; Hill et al., 1990a).
We have previously described cisplatin resistance in a
murine fibrosarcoma cell line (SSK-cis), induced by intermit-
tent low dose cisplatin treatment (Eichholtz-Wirth et al.,
1993). This drug resistance was transient and was charac-
terised mainly by elevated metallothionein content.
In the present study we report on cisplatin resistant SSK-
rad cells that were isolated after fractionated irradiation
without any prior drug treatment. The following experiments
were performed to identify the mechanisms underlying this
radiation induced drug resistance and to compare them to
those after cisplatin induction. The data could help to clarify
whether the way of generating resistance determines the oper-
ating mechanism of resistance, as suggested by Hill et al.
(1990b).
Materials and methods
Cell lines and induction ofresistance
Mouse fibrosarcoma cells (SSK) were grown as monolayer
culture in Eagle's minimal essential medium (MEM), supple-
mented with 10% calf serum, 0.01% neomycin, and 0.035%
NaHCO3, in a humidified CO2 incubator at pH 7.4 and 37°C.
Their mean doubling time was 12 h.
About 106 cells were exposed to fractionated y-irradiation
(6 Gy per fraction), using a gamma cell 40 caesium-137
source (AECL-Industria, Canada) at a dose rate of 1.2 Gy
min-'. After each fraction the cells were allowed to grow
until confluency at which time irradiation was repeated up to
a total dose of 90 Gy. Twelve clones, denoted SSK-rad, were
isolated. These clones exhibited cisplatin resistance. Clone
SSK-rad, was used for all experiments. SSK-rad, cells are
more elongated than the parental cells but they didn't differ
in cell size. Their colonies exhibit more fascicular growth
whereas the SSK colonies rather pile up in the centre.
Induction of cisplatin resistance by drug treatment has
been described elsewhere (Eichholtz-Wirth et al., 1992).
Briefly, cisplatin resistance was generated by exposure of 105
SSK cells to 10 g ml cisplatin for 1 h. Subsequently, the
cells were allowed to grow to confluency at which time the
treatment was repeated. After only 3-5 treatment cycles,
resistant clones, designated SSK-cis, were isolated and sub-
cultured in drug free medium. In this study clone SSK-cis2
was used which is identical to SSK-R2, previously charac-
terised. The drug induced cisplatin resistant cells are denoted
now SSK-cis, to differentiate from the radiation induced
cisplatin resistant cells SSK-rad. They have similar growth
characteristics as the SSK-rad, cells.
Measurement ofdrug and radiation sensitivity
Exponentially growing cells of SSK-rad and SSK-cis clones
were subcultured, appropriately diluted and allowed to attach
to the glass surface overnight. Exposure to cisplatin (cisplatin
solution, Behring, Marburg, Germany) was carried out in
culture medium for 1 h at different drug concentrations. The
drug was diluted in Hanks' solution and added to the culture
medium (maximum cell number of 10,000). After the allotted
exposure time the medium was decanted, the cells rinsed with
Hanks' solution and fresh culture medium was added.
For cadmium chloride (CdCI2) toxicity studies, cells were
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exposed for 1 h to various concentrations of CdCI2.
For radiation treatment, cells were exposed to graded sin-
gle doses of y-rays from a gamma cell 40 caesium-137 source
at a dose rate of 1.2 Gymin-'.
Following any of the indicated treatments, cells were incu-
bated for either 8 days (SSK cells) or 10 days (SSK-rad and
SSK-cis sublines). The colonies were then stained with
methylene blue and those containing more than 50 cells were
counted. The surviving fraction (SF) was calculated from the
ratio of mean colony yield of treated to untreated cells. All
experiments were carried out with four replicate bottles and
repeated at least three times. Experimental data were accept-
ed if the colony forming efficiency of the untreated cells was
higher than 35%.
Resistance factor (Rf) was defined as the ratio of drug
doses, D., of resistant over parent SSK cells.
Cellular cisplatin concentration
The cellular concentration of platinum was determined with
proton-induced characteristic X-ray emission (PIXE) as de-
scribed in detail by Eichholtz-Wirth et al. (1990 and 1992).
After exposure of 106 cells to 0, 10, 20 and 40 tgml1I
cisplatin for 1 h, cellular platinum content was determined.
Regression lines were calculated (correlation coefficient
>0.99) and the cellular platinum content compared.
GSH andprotein determination
Cells in the logarithmic growth phase were used for GSH-
determination according to Tietze (1969). GSH S-transferase
(GST) was assayed according to the method of Habig et al.
(1974), using 1-chloro-2,4-dinitrobenzene (CDNB) as sub-
strate. GST activity is expressed as nmol GSH-CDNB
conjugate formed per minmg-' protein. For protein deter-
mination the Lowry assay was used (Lowry et al., 1951).
Metallothionein test
Cells were tested for metallothionein content by binding of
radioactive "0Cd to the cytosol followed by FPLC. An ali-
quot of 5 x 106 exponentially growing SSK or SSK-rad cells
were harvested by trypsination and washed twice with PBS
(4°C). The cells were disrupted by sonification and then
centrifuged (20,000 g for 20 min). The supernatant was
incubated with trace amounts of '09Cd for 30 min at 37°C.
Thereafter the solution was centrifuged (12,000 g, 2min) and
filtered through a 0.45 tim membrane filter. Aliquots of the
filtrate were injected to FPLC- gelfiltration on a Superose-12
column (300 x 1Omm), using 0.05 m sodium-phosphate pH
7.0, 0.15 M sodium chloride as eluent at a flow rate of
0.5 ml min-'. Fractions of 0.5 ml were collected and measur-
ed for radioactivity. Cadmium binding metallothionein was
identified by comparison with rabbit liver metallothionein
(Sigma).
Results
SSK-rad, clones have almost the same radiosensitivity as the
parental SSK cells as well as the drug induced cisplatin
resistant subline SSK-cis2 (Figure 1). If survival is measured
as a function of cisplatin concentration after a 1 h drug
exposure, SSK-rad, cells exhibit a distinctly enhanced drug
resistance. Resistance is only slightly less than that observed
in the SSK-cis2 cells as indicated by the Rf values of 5.8 and
7.8 respectively (Figure 2). Twelve clones were isolated that
were drug resistant; however, in this study the induction rate
of drug resistance after irradiation was not determined
systematically. The degree ofcisplatin resistance could not be
enhanced, if the resistant clones were given three additional
radiation fractions (five clones tested). For all further experi-
ments, the same SSK-rad, clone was used.
Growth characteristics of both resistant sublines are simi-
lar, colony forming efficiencies are between 60-90% as in the
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Figure 1 Radiation survival curve for parental SSK cells (-x-)
and clones SSK-rad, (-A-) and SSK-cis2 (-O-). The results
shown represent the mean of at least three experiments. The
survival curve of the SSK cells was generated using linear regres-
sion analysis.
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Figure 2 Cell survival to 1 h cisplatin exposure of the parental
SSK cells (-x-), the radiation-induced resistant clone SSK-rad, (-A-) and the drug-induced clone SSK-cis2 (-O-). The curves
were calculated by linear regression analysis; each point re-
presents the mean(±s.d.) of at least ten dishes from at least three
experiments.
parental SSK cells. Both sublines differ from SSK cells by
longer doubling times of 15-18 h as compared to 11-13 h in
the SSK cells (Table I). There is no cross resistance to other
cytostatic agents such as doxorubicin, vinblastin or melpha-
lan (Table II). Protein content is not significantly different in
all cell lines, whereas cellular drug content is reduced in
SSK-cis2 cells but not in SSK-rad, cells (Table I).
Since thiols were shown to play an important role for
cisplatin detoxification in SSK-cis cells, non-protein and pro-
tein thiols were determined in SSK-rad, cells. GSH is in-
creased by a factor of 1.9 in SSK-rad, cells compared to the
parental SSK cells but is in the normal range in SSK-cis2
cells (Table I). When resistance is lost the enhanced total
GSH level is not significantly changed. GST is slightly in-
creased in both SSK-rad, and SSK-cis2 cells. For SSK-cisCISPLATIN RESISTANCE AFTER IRRADIATION 1003
Table I Characteristics of the sensitive SSK cells and the resistant
sublines SSK-rad, and SSK-cis2
Parameter SSK SSK-rad, SSK-cis2
Doubling time (h)ab 11-13 15-18 15-18
Protein contentb 161±8 148± 12* 153±9*
(Lg (106 cells)-')
Total GSHb 14.5± 1.2 27± 2.6*** 16.5±2.2*
(nmol (mg protein)-')
GSTb (nmol (DNB 63±8 92±10** 98 ±6***
min mgprotein)-')
Cellular drug contentc 1.6 1.5 1.0
ng (106 cells)-'
aCalculated from the exponential portion of the growth curve;
bMeans±s.d. from three separate experiments; cData are derived from
the regression curves ofcellular platinum content at 20pg ml-' at 1 h
exposure time. ***P<0.01 as compared to the data ofthe SSK cells;
**P<0.05 as compared to the data of the SSK cells. *n.s.
Table II Comparison of drug resistance of parental SSK cells and
cisplatin resistant SSK-rad, and SSK-cis2 cells
Cytostatic drug SSK SSK-rad,a SSK-cis2a
Melphalan 3.6 3.8 3.9
Doxorubicin 6.4 5.6 5.8
Vinblastin 4.2 4.8 5.0
'C90drugconcentration necessarytoreducecellsurvival to10% after
1 h drug exposure; data are derived from the survival curves and are
expressed as fig ml- .
cells, reduced CdC12 toxicity, an indirect measure of MT, was
shown to correlate with drug resistance and to increase, when
the transient drug resistance was lost. Therefore it was tested
whether the same mechanism is also responsible for cisplatin
resistance in SSK-rad, cells. Figure 3 demonstrates that
CdCl2 toxicity is reduced to almost the same extent in SSK-
rad, cells as in SSK-cis2 cells. The CdCl2 concentration neces-
sary to reduce survival to 10% is by a factor of 2.0 (SSK-
rad, cells) and 2.2 (SSK-cis2 cells) higher in the resistant cells
than in the parental SSK cell lines. After 10-20 passages,
cisplatin resistance decreases in SSK-rad, cells. Figure 4 dem-
onstrates the loss of drug resistance between passages
number 9 and 13. This loss of drug resistance coincides with
an increase in CdCl2 toxicity (Figure 5). Various SSK-rad
clones that were isolated and tested had the same characteris-
tics as described above; only the time they retained their
cisplatin resistance differed, lasting from only 10 passages (as
shown in Figures 4 and 5) to 25-30, corresponding to
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Figure 3 Cell survival as a function of cadmium chloride con-
centration after a 1 h exposure. Symbols are as in Figure 2. Each
point represents the mean (±s.d.) of at least ten dishes from at
least three experiments.
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Figure 4 Cell survival as a function of cisplatin concentration
after 1 h drug exposure when the cells lose their drug resistance
(-x-): parental SSK cells; open triangles: resistant subline SSK-
rad, (passage number 9; -A-); closed triangles: same subline,
when cisplatin resistance diminishes (passage numbers 12 and 13).
Curves -x - and -A- are the same as in Figure 2.
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Figure 5 Cell survival after a 1 h CdCI2 exposure when cisplatin
resistance diminishes (-x-): parental SSK cells; open triangles:
resistant subline SSK-rad, passage number 9; closed triangle:
same subline, when resistance decreases (passage number 12).
Curves -x- and -A- are the same as in Figure 2.
120-150 cell cycles. Five passages after loss of cisplatin
resistance, revertant cell lines did not retain the same cis-
platin sensitivity as the parental cells (RF = 1.6); doubling
times remained longer. The revertants were then no longer
followed up.
Increased metallothionein (MT) content is measured direct-
ly by specific binding of trace amounts of 'MCd to the
cytosolic fractions (Figure 6). In this semiquantitative assay,
fraction numbers 31 to 33 correspond to the MT region
(molecular weight of 6,000-10,000). These fractions contain
27% of the cumulative activity in the SSK-rad, cells and only
11% in the parental SSK cells. In contrast, in the GSH
region (fractions 36-38), the "'0Cd activity is not significantly
increased in the SSK-rad, cells as compared to the parental
cells. As a result of these changes, SSK-rad, cells contain
only 17% of the "'9Cd activity in the high molecular weight
region but the amount is 30% in the parental SSK cells.
Discussion
In this study we have demonstrated that cisplatin resistance
can be induced in murine fibrosarcoma cells in vitro by
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Figure 6 FPLC chromatograms of "'Cd labelled cytosol fractions of parental SSK a, and SSK-rad, cells b, with '0Cd binding
( ) and UV absorption (.). Fraction numbers 31 to 33 correspond to the MT region.
ionising irradiation without prior drug treatment. This
acquired drug resistance is not associated with a decrease in
radiosensitivity. The mechanisms leading to transient cis-
platin resistance are similar to those described after cisplatin
induced resistance (Eichholtz-Wirth et al., 1993). Both in
subclones SSK-rad1 and SSK-cis2, several mechanisms may
contribute to cisplatin resistance: however, the main factor
correlating with the development and loss of cisplatin resis-
tance is the cellular content of metallothioneins.
These enhanced MTs do not confer radiation resistance,
although they are suggested to play a role in radiation pro-
tection by scavenging hydroxyl and superoxide radicals
(Thornalley & Vasak, 1985). Matsubara et al. (1987) showed
that the induction of MTs in mouse liver is a significant factor
for radiation protection. Also, Hodgkiss (1990) described
higher endogenous levels of protein and non-protein thiols in
irradiated cells which might reduce the efficacy of radiation
itself. Similar to our findings, he observed that the resistant
phenotypes can persist through many cell generations in the
absence of selection pressure but eventually revert to the
same phenotype as the unirradiated population. This suggests
that there is no classical gene mutation. However, he did not
correlate the increased thiols to the cytotoxic effect ofchemo-
therapeutic agents. In both of our resistant SSK-rad1 and
SSK-cis2 clones, increased MT content also lasts for a limited
number of generations and it is associated with transient
cisplatin resistance, but not with radioresistance. This is inde-
pendent of the selection procedure. As hypothesised by
Kaina et al. (1990), MTs are required to be in close proxim-
ity to the DNA in order to neutralise free radicals in the
nucleus and to be an efficient radical scavenger. These
authors conclude, - which may be confirmed by our data -,
that MT concentrations in the nucleus are probably insuffic-
ient for radiation protection. Our results also correspond to
those of Miura and Sasaki (1990), using mouse squamous
carcinoma cells, demonstrating that the MT level does not
determine intrinsic radiosensitivity. These authors also con-
firm that the cytotoxic effect of Cd is correlated to the MT
content; however, they did not compare the MT level and the
cellular sensitivity to cisplatin. Data of Kelley et al. (1988)
also indicate that cells with acquired resistance to cisplatin
frequently have an increased MT level and overexpress MT
mRNA. There is no evidence for gene amplification, suggest-
ing enhanced rate of gene transcription or increased mRNA
stability. Reversal of cisplatin resistance is also accompanied
by a decrease in MT content.
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Comparison of the two differently derived sublines SSK-
rad1 and SSK-cis2 shows that only SSK-rad1 cells exhibit
elevated levels of total GSH content which remain elevated
also after loss of drug resistance. Moreover, the importance
of MTs relative to GSH content for cisplatin resistance is
demonstrated by FPLC: the '09Cd activity was unchanged in
the GSH fraction but it was 2.5 times higher in the MT
region in SSK-rad1 cells compared to the parental SSK cells.
SSK-cis2 cells differed from SSK-rad, cells by reduced
cellular platinum content, which was also unchanged upon
loss of cisplatin resistance (Eichholtz-Wirth et al., 1993).
These factors - increased GSH in SSK-rad, cells and reduced
cellular platinum content in SSK-cis2 cells - may contribute
to cisplatin resistance in the two sublines, showing that the
mechanisms involved in cisplatin resistance are multifactorial.
However, the dominating factor that correlates with the tran-
sient nature ofcisplatin resistance is the elevation of the MTs
and this is demonstrated for both sublines.
This is also stressed by our data on cross resistance to
doxorubicin, melphalan and radiation. Cross-resistance to
these agents and radiation is reported mainly in cells with
altered Pt-DNA binding, reduced cross-links and elevated
GSH levels or GSH-dependent enzymes (Hamilton et al.,
1985; Hospers et al., 1988). Since there is no cross resistance
in SSK-cis2 and SSK-rad1 cells, this would also suggest other
mechanisms responsible for the acquisition of cisplatin resis-
tance in SSK cells.
Resistance has been demonstrated to be multifactorial not
only for drug induced resistance but also for radiation
induced cisplatin resistance, as also reported by Dempke et
al. (1992). In their human ovarian cells, resistance was
associated mainly with enhanced repair and increased toler-
ance of DNA damage; cisplatin uptake was decreased and
cytotoxicity could be enhanced by verapamil, but not by
inhibition of GSH with BSO. In our SSK cells, verapamil has
no effect on SSK and SSK-cis2 cells (Eichholtz-Wirth, 1993),
whereas BSO treatment may be used to increase cisplatin
toxicity for the sensitive and resistant cells (Eichholtz-Wirth,
1993; data for SSK-rad1 cells not shown). DNA repair was
not studied in our SSK cells.
Drug resistance after fractionated irradiation was described
in a series of publications by the group of Hill et al. (1988-
1990b) for various cellular systems. These authors propose
that the patterns of response to antitumour drugs and the
associated mechanisms differ depending on the agent employ-
ed to induce resistance. According to our results a similar
pattern of resistance may rather develop in one model
system, independent of the way how drug resistance was
induced. This agrees with data on MTX resistance after
radiation in different cells by Sharma and Schimke (1989).
They suggest that different tumour cell types may have differ-
ing propensities for developing MTX resistance by different
mechanisms. Moreover, the degree of resistance, which is
also supposed to correlate to the way ofinduction and which
is usually enhanced upon increasing treatment doses, is only
slightly lower in SSK-rad, cells compared to SSK-cis2 cells
and cannot be enhanced either by additional irradiation
(SSK-rad cells) or by further drug exposure (SSK-cis2 cells).
In our study as well as in most of the published data cited
above cisplatin resistance was generated after high dose frac-
tionated radiation. It remains to be determined now whether
this induction ofcisplatin resistance is a general phenomenon
also after a low total radiation dose as well as lower dose per
fraction in vitro and in vivo. These data may have implica-
tions for combined modality therapy using sequential or
simultaneous drug and radiation treatment.
Abbreviations: BSO, buthionine sulfoximine; CDNB, l-chloro-2,4-
dinitrobenzene; Cisplatin, cis-diamminedichloroplatinum (II); FPLC,
fast protein liquid chromatography; GSH, glutathione; GST, gluta-
thione S-transferase; MT, metallothionein; Rf, resistance factor;
SF, surviving fraction.
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